Skip to main content
letter
. 2022 Apr 9;35(6):1775–1776. doi: 10.1007/s40620-022-01319-8

Fig. 1.

Fig. 1

Positivity for SARS-CoV-2. A The 29 positive subjects were not vaccinated for SARS-CoV-2 at the time of infection. None of the vaccinated patients developed SARS-CoV-2 infection (p = 0.0011). B Prevalence of infection in patients receiving rituximab is statistically significant when compared to subjects receiving MMF (p = 0.03)